<article id="resources" class="slide" data-ag-name="Resources">
  <h1>References</h1>
  <div class="text">
    <div class="section">
      <ol id="reference-group1">

        <li class="clearfix reference indent1" data-pdf="content_EN/pdf/Eylea_PM_10DEC2015.pdf" id="reference-1">
          <div class="pdf-icon">EYLEA<sup class="reg">&reg;</sup> Product Monograph, Bayer Inc., December 10, 2015.</div>
        </li>
        <li class="clearfix reference indent1" data-pdf="content_EN/pdf/DOF_Bayer-Med_VGF-and-PGF-November-2016.pdf" id="reference-2">
          <div class="pdf-icon">Data on file, November 2016, Bayer Inc.</div>
        </li>
        <li class="clearfix reference indent1" data-pdf="content_EN/pdf/Korobelnik_et_al_VIVID-VISTA_Ophthalmology_July_2014.pdf" id="reference-3">
          <div class="pdf-icon">Korobelnik JF, Do DV, et al. Intravitreal aflibercept for diabetic macular edema. <i>Ophthalmology</i> 2014:2247–54.</div>
        </li>
        <li class="clearfix reference indent1" data-pdf="content_EN/pdf/Boyer_COP_6 MOS.pdf" id="reference-4">
          <div class="pdf-icon">Boyer D, Heier J, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: Six-month results of the Phase 3 COPERNICUS study. <i>Ophthalmology</i> 2012;119:1024–32.</div>
        </li>
        <li class="clearfix reference indent1" data-pdf="content_EN/pdf/Clark-VIBRANT-52-week-results.pdf" id="reference-5">
          <div class="pdf-icon">Clark WL, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion 52-week results of the VIBRANT study.<br><i>Ophthalmology</i> 2016;123(2):330–336.</div>
        </li>

        <li class="clearfix reference indent1" data-pdf="content_EN/pdf/DOF_May_2016.pdf" id="reference-6">
          <div class="pdf-icon">Data on file, May 2016, Bayer Inc.</div>
        </li>
        <li class="clearfix reference indent1" data-pdf="content_EN/pdf/Talks-J-S-et-al-Ophthalmology-2015.pdf" id="reference-7">
          <div class="pdf-icon">Talks JS, et al. First-year visual acuity outcomes in the United Kingdom of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. <i>Ophthalmology</i> 2016;123(2):337–43.</div>
        </li>

      </ol>
    </div>
  </div>
  
  <div class="footer">
    <p>&copy; 2017, Bayer Inc.</p>
    <p>&reg; TM see www.bayer.ca/tm-mc</p>
    <div class="reference-logos">
      <img src="content_EN/img/graphics_member-logo-EN.png" width="180" height="21" />
      <img src="content_EN/img/graphics_PAAB-logo.png" width="45" height="20" />
    </div>
    <p class="version">L.CA.MKT.10.2016.1915</p>
  </div>
</article>